IPATF News and Press, ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies (NASDAQ:IPA) said its antibody cocktail PolyTope TATX-03 showed strong neutralizing activity against Omicron subvariant BA.2 in lab test. In-vitro data showed that the BA.2 pseudovirus was neutralized with a potency comparable to the previously analyzed Omicron B...

ImmunoPrecise Antibodies (IPATF) has announced the identification of antibody 23-H7, which preclinical data obtained to date indicates provides strong, protective anti-viral effects in SARS-CoV-2 (COVID-19) infected Syrian hamsters via an uncommon mechanism of action.In vivo efficac...

Therapeutic antibody discovery and development company ImmunoPrecise Antibodies' (IPATF) shares have been approved for listing on the NASDAQ Global Market under the trading ticker symbol "IPA."Trading is expected to commence on December 30.The company's shares will continue to trade on TSX Ve...

ImmunoPrecise Antibodies to Begin Trading on Nasdaq Stock Exchange Canada NewsWire VICTORIA, BC , Dec. 23, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV: IPA) (Nasdaq Global Markets: IPA), a leader in full-service, therapeu...

ImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter of 2021 Fiscal Year Canada NewsWire Record Quarterly Revenue of $4,754,545 and Adjusted EBITDA of $795,159 Announced Strategic Partnership ...

Immunoprecise Antibodies ([[IPATF]]) and LiteVax have nominated a lead COVID-19 vaccine candidate for further (pre-) clinical evaluation and development based on results from their collaborative preclinical immunogenicity study.Immunization of swine with a low dose of the selected candidate r...

ImmunoPrecise and LiteVax Advance SARS-CoV-2 Vaccine Candidate VICTORIA, BC , Dec. 14, 2020 /PRNewswire/ - IMMUNOPRECISE ANTIBODIES LTD. ("IPA") (TSXV: IPA) (IPATD: IPA) (FSE: TQB), a leader in full-service, therapeutic antibody discovery and development and LiteVax...

Immunoprecise Antibodies (IPATF) has announced a research collaboration with Human Health Therapeutics Research Centre of National Research Council of Canada to develop to develop its neutralizing PolyTope™ antibodies against SARS-CoV-2.For pre-clinical and clinical manufacturing of it...

ImmunoPrecise Antibodies Ranked Number 240 Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™ Canada NewsWire VICTORIA, BC, Nov. 25, 2020 VICTORIA, BC , Nov. 25, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or...

IPA Selects Polytope™ Formulations for Pre-Clinical Studies PR Newswire VICTORIA, BC, Nov. 23, 2020 VICTORIA, BC , Nov. 23, 2020 /PRNewswire/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE: TQB2), a...